NAMS Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
3.7M
+21.7%
3.0M
+9400.0%
32.0K
-90.8%
348.0K
-98.2%
19.1M
Cost of Revenue
0
0
0
0
0
Gross Profit
3.7M
+21.7%
3.0M
+9400.0%
32.0K
-90.8%
348.0K
-98.2%
19.1M
Operating Expenses
68.6M
+11.6%
61.5M
-6.9%
66.0M
+19.0%
55.5M
+1.3%
54.8M
R&D
41.7M
+9.6%
38.0M
-1.5%
38.6M
+24.6%
31.0M
+12.6%
27.5M
SG&A
26.9M
+14.7%
23.5M
-14.5%
27.4M
+11.8%
24.5M
-10.1%
27.3M
Operating Income
-64864000
-11.0%
-58420000
+11.5%
-65980000
-19.7%
-55143000
-54.7%
-35635000
EBITDA
-64805000
-11.0%
-58358000
+11.5%
-65921000
-19.7%
-55079000
-54.8%
-35590000
Net Income
-64135000
-32.4%
-48441000
+35.3%
-74923000
-4.1%
-72005000
-314.7%
-17364000
EPS (Basic)
$-0.52
-30.0%
$-0.40
+35.5%
$-0.62
-1.6%
$-0.61
-306.7%
$-0.15
EPS (Diluted)
$-0.52
-30.0%
$-0.40
+35.5%
$-0.62
-1.6%
$-0.61
-306.7%
$-0.15
Shares (Diluted)
123.4M
+1.4%
121.7M
+1.4%
120.0M
+0.9%
119.0M
+0.4%
118.6M
NewAmsterdam Pharma Company N.V. (NAMS) โ€” Financials